MoonLake Immunotherapeutics (MLTX) Minority Interest (2022 - 2025)

MoonLake Immunotherapeutics' Minority Interest history runs 4 years deep, the most recent figure standing at $2.3 million for Q3 2025.

• On a quarterly basis, Minority Interest fell 68.73% year-over-year to $2.3 million in Q3 2025; TTM through Sep 2025 was $2.3 million, a 68.73% decrease from a year earlier, with the FY2024 full-year figure at $6.6 million, down 63.14% from the prior year.
• Minority Interest declined to $2.3 million in Q3 2025 per MLTX's latest filing, from $4.2 million in the prior quarter.
• Across five years, Minority Interest topped out at $64.7 million in Q3 2023 and bottomed at $2.3 million in Q3 2025.
• The 4-year median for Minority Interest is $9.6 million (2024), against an average of $16.6 million.
• Across the five-year window, Minority Interest jumped 137.2% in 2023 and slumped 88.71% in 2024, its largest moves.
• Year by year, Minority Interest stood at $19.9 million in 2022, then retreated by 10.33% to $17.8 million in 2023, then sank by 63.14% to $6.6 million in 2024, then tumbled by 65.2% to $2.3 million in 2025.
• Per Business Quant, the three latest MLTX Minority Interest figures stand at $2.3 million (Q3 2025), $4.2 million (Q2 2025), and $5.1 million (Q1 2025).